Clarity Pharmaceuticals | LinkedIn (original) (raw)

Biotechnology Research

Sydney, NSW 9,790 followers

Clarity is developing next-generation products to address the growing need for radiopharmaceuticals in oncology.

View all 55 employees

About us

Clarity is a clinical stage radiopharmaceutical company developing next-generation products to address the growing need for the use of radiopharmaceuticals in oncology. Clarity is a global leader in Targeted Copper Theranostics (TCT), developed with its proprietary SAR Technology platform. TCT are the next-generation disruptive platform in radiopharmaceuticals that employ the “perfect pairing” of copper-64 and copper-67 for diagnosis and therapy. TCT deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as providing supply and logistical advantages over current theranostics. TCT provide a highly efficacious, scalable, and cost-effective way to expand radiopharmaceuticals into the global oncology market. Clarity has a diverse range of products in clinical trials which address both large indications (prostate cancer and breast cancer) as well as small and orphan indications (neuroendocrine tumours (NETs) and neuroblastoma) of cancer. Our ultimate goal is to improve treatment outcomes for children and adults with cancer.

Industry

Biotechnology Research

Company size

11-50 employees

Headquarters

Sydney, NSW

Type

Public Company

Founded

2010

Specialties

Antibody and peptide imaging, Pharmaceutical imaging, Companion diagnostics, Drug development, Radiopharmaceuticals, Nuclear medicine, and Targeted therapy

Locations

Employees at Clarity Pharmaceuticals

Updates

Clarity’s exceptional position in the radiopharmaceutical market is underpinned by its strong roots in great Australian science and dedicated team with unique expertise. These not only resulted in a pipeline of best-in-class products in clinical trials, but also laid the foundation for a number of exciting new technologies, products and indications in preclinical development, paving the way for future innovation. With a strong financial position to support its growth and the radiopharmaceutical field generating a lot of excitement, Clarity’s future has never looked brighter. Watch season 2 episode 7 below, featuring Clarity’s Executive Chairperson, Dr Alan Taylor, and Wilsons Advisory's Deputy Head of Research, Melissa Benson, to learn more about what is next for Clarity and its pipeline of best-in-class products in development. #podcast #radiopharmaceuticals #biotech
Clarity receives FDA Fast Track Designation for its diagnostic 64Cu-SAR-bisPSMA product. This designation, which is designed to expedite the development and regulatory review of novel drugs addressing serious conditions with significant unmet medical needs, provides a number of benefits in the development of 64Cu-SAR-bisPSMA, potentially reducing the New Drug Application (NDA) review time, allowing more frequent meetings with the FDA during development, and allowing Rolling Review of the planned NDA. The Fast Track Designation is supported by the initial clinical evidence suggesting that 64Cu-SAR-bisPSMA may offer improved lesion detection compared to existing prostate cancer diagnostics. It comes at a time when Clarity is actively recruiting into its first registrational Phase III trial, CLARIFY, and preparing for an End of Phase meeting with the FDA for a second pivotal Phase III trial with 64Cu-SAR-bisPSMA. Clarity is committed to advancing the development of this product to address the critical need for more accurate and accessible diagnostic tools in prostate cancer management.#biotech #radiopharmaceuticals #PSMA
Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging https://www.claritypharmaceuticals.com
Clarity is committed to developing next-generation radiopharmaceuticals that provide safe and effective treatments for patients and offer a reliable, scalable and environmentally friendly solution to manufacturing and supply chain issues plaguing the current generation of products. Being able to not only develop, but also successfully deliver life changing radiopharmaceuticals to a large number of cancer patients is essential for radiopharmaceuticals to grow in the large oncology market and improve lives of people with this insidious disease. Cu-67 is produced in high quantities on electricity-powered electron accelerators, a process that is easily scalable to reach the future demand for radiopharmaceuticals globally. This is in contrast to the current process for producing Lu-177, which is reliant on an aging fleet of uranium-powered nuclear reactors that experience frequent and prolonged maintenance shutdowns, leading to shortages of these essential cancer treatments. Watch the video to learn more about the differences in the Cu-67 and Lu-177 manufacturing process and the numerous benefits the production and supply of Cu-67 can achieve.
Radiopharmaceuticals are the next frontier in oncology, but the current generation of products is barely scratching the surface of this massive opportunity. From rolling out into new indications and diseases to combination therapies, the possibilities are endless. Driven by strong efficacy and safety data, its proprietary platform technology and numerous supply and manufacturing benefits enabled by copper isotopes, Clarity is well positioned to roll out its pipeline of radiopharmaceuticals and meet the demand for better treatments. Watch season 2 episode 5 below, featuring Clarity’s Executive Chairperson, Dr Alan Taylor, and Wilsons Advisory's Deputy Head of Research, Melissa Benson, to learn about the future of radiopharmaceuticals and emerging trends in the field.

Join now to see what you are missing

Join now

Clarity Pharmaceuticals | LinkedIn (original) (raw)

Biotechnology Research

Sydney, NSW 9,790 followers

Clarity is developing next-generation products to address the growing need for radiopharmaceuticals in oncology.

About us

Locations

Employees at Clarity Pharmaceuticals

Updates

Join now to see what you are missing

Similar pages

Browse jobs

Funding